ArticleFrontiers in oncology2025
Prediction of induction chemotherapy efficacy in patients with locally advanced nasopharyngeal carcinoma using habitat subregions derived from multi-modal MRI radiomics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Performance of magnetic-resonance imaging radiomics in prediction of response after neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A systematic review and meta-analysis.European journal of radiology open · 2026Article
- Development and validation of a radiomics-habitat model for preoperatively predicting poorly differentiated stage IA lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Article
- CT-based habitat analysis combined with multi-channel deep learning for predicting early recurrence after pancreatic cancer resection: a multicenter study.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to predict the early efficacy of induction chemotherapy (ICT) in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) through habitat subregion analysis and multimodal MRI radiomics techniques. Methods: The study employed a retrospective design and included LA-NPC patients who received ICT treatment between 2015 and 2019. The K-means clustering algorithm was utilized to segment the tumor into five distinct habitat subregions based on imaging features. A total of 2,153 radiomic features, including geometric shape, intensity, and texture features, were extracted. Feature selection was conducted using the maximum relevance minimum redundancy (mRMR) method and the least absolute shrinkage and selection operator (LASSO) technique. Eleven machine learning algorithms were employed to develop radiomics models based on the CE-T1WI and T2-FS sequences, respectively. These models were evaluated using various predictive performance metrics, including area under the curve (AUC), sensitivity, and specificity. Model selection was based on comprehensive cross-validation performance and AUC values. Results: The study population comprised 76.63% males and 23.37% females, with a mean age of 42.60 ± 10.21 years. All patients had stage III to IVa nasopharyngeal carcinoma, and the majority (92.39%) had non-keratinizing squamous cell carcinoma. Habitat subregion analysis revealed that the volume features of a specific subregion (Subregion 2) were significantly associated with patient response to ICT ( Conclusion: Habitat subregion analysis using multimodal MRI radiomics offers an effective approach for the early identification of LA-NPC patients with poor responses to induction chemotherapy. This method holds promise for supporting clinical treatment decisions and achieving personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.